I see. Have you ever invested in small bio tech companies before ? Most other bio tech firms with similar caps don't have approved drugs or their approved drugs has a limited potential. On the other hands, Savient's K had been approved with strong patents to address larger markets and they have enough monies to launch the product worldwide.
I cannot say what the stock would look like for the next 3 months. But I would be surprised if the stock is not at least high teens by the end of this year.